171 related articles for article (PubMed ID: 20819888)
21. Rosiglitazone and the FDA.
Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
[No Abstract] [Full Text] [Related]
22. FDA puts rosiglitazone post-marketing trial on hold.
Cohen D
BMJ; 2010 Jul; 341():c4017. PubMed ID: 20660507
[No Abstract] [Full Text] [Related]
23. European regulatory body recommends suspension of rosiglitazone.
Cohen D
BMJ; 2010 Sep; 341():c5291. PubMed ID: 20870700
[No Abstract] [Full Text] [Related]
24. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.
Woodcock J; Sharfstein JM; Hamburg M
N Engl J Med; 2010 Oct; 363(16):1489-91. PubMed ID: 20942663
[No Abstract] [Full Text] [Related]
25. The rosiglitazone decision process at FDA and EMA. What should we learn?
Pouwels KB; van Grootheest K
Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
[TBL] [Abstract][Full Text] [Related]
26. European drug regulators publish their evaluation of rosiglitazone.
Mayor S
BMJ; 2010 Dec; 341():c7278. PubMed ID: 21169326
[No Abstract] [Full Text] [Related]
27. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
Gorman C
Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
[No Abstract] [Full Text] [Related]
28. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
29. Drug safety. Planned study of Avandia in doubt after FDA review.
Kean S
Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123
[No Abstract] [Full Text] [Related]
30. The painful truth.
Nissen SE
Eur Heart J; 2010 May; 31(10):1284-5. PubMed ID: 20418344
[No Abstract] [Full Text] [Related]
31. Anticipated US approval for rosiglitazone and pioglitazone.
Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
[No Abstract] [Full Text] [Related]
32. [Wrong choice of antidiabetics can be disastrous].
Sjöholm A
Lakartidningen; 2010 Sep 29-Oct 5; 107(39):2300-1. PubMed ID: 20973243
[No Abstract] [Full Text] [Related]
33. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
34. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
Kaul S; Bolger AF; Herrington D; Giugliano RP; Eckel RH; ;
J Am Coll Cardiol; 2010 Apr; 55(17):1885-94. PubMed ID: 20413044
[No Abstract] [Full Text] [Related]
35. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
[No Abstract] [Full Text] [Related]
36. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
Vaccaro O; Riccardi G
Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715
[No Abstract] [Full Text] [Related]
37. Playing the numbers game.
Drug Ther Bull; 2011 Jan; 49(1):1. PubMed ID: 21220251
[No Abstract] [Full Text] [Related]
38. Rosiglitazone: a case of regulatory hubris.
Nissen SE
BMJ; 2013 Dec; 347():f7428. PubMed ID: 24335808
[No Abstract] [Full Text] [Related]
39. European drug agency extends review of safety of pioglitazone.
Moynihan R
BMJ; 2011 Jun; 342():d4105. PubMed ID: 21715461
[No Abstract] [Full Text] [Related]
40. European Medicines Agency must take account of cardiovascular harm associated with degludec insulin.
Schmidt TA; Rosen CJ; Yudkin JS
BMJ; 2013 Jun; 346():f3731. PubMed ID: 23757746
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
